Cited by 18Pharmacogenetics and Drug MetabolismRenal Transplantation Outcomes and TreatmentsGenetic Associations and Epidemiology

An Integrated Clinical and Genetic Prediction Model for Tacrolimus Levels in Pediatric Solid Organ Transplant Recipients

Open access
Min, Sandar, Papaz, Tanya, Lambert, A. Nicole, Allen, Upton, Birk, Patricia, Blydt-Hansen, Tom, Foster, Bethany J., Grasemann, Hartmut +12 more·2022·Transplantation

Abstract

BACKGROUND: There are challenges in achieving and maintaining therapeutic tacrolimus levels after solid organ transplantation (SOT). The purpose of this genome-wide association study was to generate an integrated clinical and genetic prediction model for tacrolimus levels in pediatric SOT. METHODS: In a multicenter prospective observational cohort study (2015-2018), children <18 years old at their first SOT receiving tacrolimus as maintenance immunosuppression were included (455 as discovery cohort; 322 as validation cohort). Genotyping was performed using a genome-wide single nucleotide polymorphism (SNP) array and analyzed for association with tacrolimus trough levels during 1-y follow-up. RESULTS: Genome-wide association study adjusted for clinical factors identified 25 SNPs associated with tacrolimus levels; 8 were significant at a genome-wide level (P < 1.025 × 10-7). Nineteen SNPs were replicated in the validation cohort. After removing SNPs in strong linkage disequilibrium, 14 SNPs remained independently associated with tacrolimus levels. Both traditional and machine learning approaches selected organ type, age at transplant, rs776746, rs12333983, and rs12957142 SNPs as the top predictor variables for dose-adjusted 36- to 48-h posttacrolimus initiation (T1) levels. There was a significant interaction between age and organ type with rs776476*1 SNP (P < 0.05). The combined clinical and genetic model had lower prediction error and explained 30% of the variation in dose-adjusted T1 levels compared with 18% by the clinical and 12% by the genetic only model. CONCLUSIONS: Our study highlights the importance of incorporating age, organ type, and genotype in predicting tacrolimus levels and lays the groundwork for developing an individualized age and organ-specific genotype-guided tacrolimus dosing algorithm.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/tp.0000000000003700

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Using combination of genomic data and clinical factors was shown more important than the choice of algorithm.

    “Using combination of genomic data and clinical factors was shown more important than the choice of algorithm.”
  • All three studies comparing logistic regression to machine learning algorithms for predicting stable tacrolimus dose in kidney transplant patients showed a superior predictive ability of machine learning tools over linear regression models, albeit with a relatively small difference.

    “All studies showed a superior predictive ability of machine learning tools over the linear regression models, albeit with a relatively small difference.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Min, S., Papaz, T., Lambert, A. N., Allen, U., Birk, P., Blydt-Hansen, T., Foster, B. J., Grasemann, H., Hamiwka, L., Litalien, C., Ng, V., Berka, N., Campbell, P., Daniel, C., Saw, C. L., Tinckam, K., Urschel, S., Van Driest, S. L., Parekh, R., & Mital, S.
Affiliations
  • Hospital for Sick Children (CA)
  • Vanderbilt University Medical Center (US)
  • University of Toronto (CA)
  • Health Sciences Centre (CA)
  • Division of Pediatric Nephrology, University of British Columbia, Vancouver, BC, Canada.
  • Montreal Children's Hospital (CA)
  • University of Calgary (CA)
  • Centre Hospitalier Universitaire Sainte-Justine (CA)
  • University of Alberta (CA)
  • Institut National de la Recherche Scientifique (CA)
  • McGill University Health Centre (CA)
  • University Health Network (CA)
  • Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
Corresponding author
Mital, Seema
Venue
Transplantation
Published
2021-02-22
Volume
106
Issue
3
Pages
597-606
ISSN
0041-1337 (ISSN-L)
OpenAlex
W3135603479
Cited by
18
References
46
Citations by year
2026: 1 · 2025: 1 · 2024: 6 · 2023: 6 · 2022: 3 · 2021: 1
FWCI
3.66
Type
journal article
Language
en
Open access
Locations
  • Transplantation (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • EspaceINRS (National Institute for Scientific Research (Canada)) (submittedVersion)
Funders
  • Burroughs Wellcome Fund (1015006, IRSA 1015006)
  • Heart and Stroke Foundation of Canada
  • Vanderbilt University (UL1 RR024975, UL1‐TR000445)
  • Vanderbilt University Medical Center (UL1TR000445, S10RR025141, UL1 RR024975, UL1 TR002243)
  • Canada Research Chairs
  • Astellas Pharma
  • Hospital for Sick Children
  • National Institutes of Health (UL1TR000445, UL1TR002243)
  • Canadian Institutes of Health Research (,TFU 127880)
  • National Heart, Lung, and Blood Institute (T32HL105334)
  • National Center for Research Resources (S10RR025141, UL1RR024975)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
tacrolimus, pediatric solid organ transplantation, pharmacogenetics, trough concentration, pharmacokinetic prediction, single nucleotide polymorphisms, rs776746, age at transplantation, genotype-guided dosing, maintenance immunosuppression
MeSH terms
Adolescent, Child, Dose-Response Relationship, Drug, Genotype, Humans, Immunosuppressive Agents, Prospective Studies, Organ Transplantation, Tacrolimus, Polymorphism, Single Nucleotide, Cytochrome P-450 CYP3A, Genome-Wide Association Study, Transplant Recipients

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review